IKT
Inhibikase Therapeutics, Inc.Company Information
- Company Name
- Inhibikase Therapeutics, Inc.
- CIK
- CIK0001750149
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- IKT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- IKT
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-21
- Last sale
- —
- Shares purchased (TTM)
- 2,068,965
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 120,107,301
- Shares outstanding
- 174,571,543
- Ownership
- 68.80%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 2.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 31 | 50 | 139 | 38 | 78 | 73 | 56 | 1 | 3 | 2 | 9 | 15 | ||||||
| Marketable Securities Current | 128 | 121 | 40 | 39 | 10 | 20 | 41 | 2 | 5 | 7 | 4 | 2 | ||||||
| Accounts And Other Receivables Net Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Deferred Offering Costs | 0 | - | - | 0 | 0 | - | - | 1 | - | - | - | - | ||||||
| Assets Current | 162 | 172 | 180 | 79 | 89 | 94 | 98 | 4 | 9 | 11 | 14 | 18 | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Noncurrent | 1 | 1 | 1 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Assets | 164 | 173 | 181 | 80 | 89 | 94 | 99 | 4 | 9 | 11 | 15 | 18 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 1 | 3 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | ||||||
| Long Term Debt And Capital Lease Obligations Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities Current | 9 | 4 | 4 | 4 | 3 | 4 | 3 | 2 | 2 | 3 | 2 | 2 | ||||||
| Liabilities Current | 10 | 6 | 8 | 7 | 9 | 9 | 4 | 5 | 4 | 4 | 3 | 3 | ||||||
| Capital Lease Obligations Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 10 | 6 | 8 | 7 | 9 | 9 | 4 | 5 | 4 | 4 | 4 | 3 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 332 | 327 | 315 | 203 | 198 | 194 | 189 | 82 | 82 | 78 | 78 | 78 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -179 | -159 | -143 | -130 | -118 | -108 | -94 | -82 | -77 | -72 | -67 | -63 | ||||||
| Stockholders Equity | 153 | 168 | 173 | 73 | 80 | 86 | 95 | -1 | 5 | 7 | 11 | 15 | ||||||
| Liabilities And Stockholders Equity | 164 | 173 | 181 | 80 | 89 | 94 | 99 | 4 | 9 | 11 | 15 | 18 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 132 | 132 | 132 | 75 | 75 | 74 | 69 | 7 | 7 | 6 | 6 | 5 | ||||||
| Shares Outstanding | 132 | 132 | 132 | 75 | 75 | 74 | 69 | 7 | 7 | 6 | 6 | 5 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInhibikase Therapeutics, Inc. (IKT) — SEC Financial Statements & Analysis
Inhibikase Therapeutics, Inc. (IKT) is a biological products, (no diagnostic substances) company, incorporated in DE. Inhibikase Therapeutics, Inc. trades on Nasdaq as: IKT. Inhibikase Therapeutics, Inc. (IKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Inhibikase Therapeutics, Inc. carries a market cap of $354.38M, a P/E ratio of -5.84x, a P/B ratio of 2.31x, a P/S ratio of 11547340.58x, an enterprise value of $323.17M, and an EV/EBITDA multiple of -4.94x. On profitability, it posts an operating margin of -2006393700.00%, a net margin of -1956524900.00%, a Return on Equity (ROE) of -51.96%, a Return on Assets (ROA) of -48.04%, and a Return on Invested Capital (ROIC) of -105.14%. Per share, it reports EPS of $-0.35, diluted EPS of $-0.35, free cash flow per share of $-0.24, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 46.10% year-over-year, and EPS growth of -24.67% year-over-year. On the balance sheet, it maintains a current ratio of 15.82x, a quick ratio of 15.59x, working capital of $152.08M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.06, an interest coverage ratio of -13.63x, free cash flow of $-42.61M (TTM), and net debt of $-31.21M. Figures sourced from SEC EDGAR.
- Market Cap
- $354.38M
- P/E TTM
- -5.84x
- EPS TTM
- $-0.35
- P/B TTM
- 2.31x
- ROE TTM
- -51.96%
- ROA TTM
- -48.04%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-42.61M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Inhibikase Therapeutics, Inc. in?
Inhibikase Therapeutics, Inc. (IKT) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does IKT trade on?
Inhibikase Therapeutics, Inc. (IKT) trades on the Nasdaq.
Where is Inhibikase Therapeutics, Inc. incorporated?
Inhibikase Therapeutics, Inc. is incorporated in DE.
When was Inhibikase Therapeutics, Inc. (IKT)'s most recent SEC filing?
Inhibikase Therapeutics, Inc. (IKT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is IKT's market cap?
Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $354.38M as of 2026-06-30.
What is IKT's EPS (earnings per share)?
Inhibikase Therapeutics, Inc. (IKT)'s trailing twelve month EPS is $-0.35 as of 2026-06-30.
What is IKT's ROE (return on equity)?
Inhibikase Therapeutics, Inc. (IKT)'s trailing twelve month Return on Equity (ROE) is -51.96% as of 2026-06-30.
What is IKT's ROA (return on assets)?
Inhibikase Therapeutics, Inc. (IKT)'s trailing twelve month Return on Assets (ROA) is -48.04% as of 2026-06-30.
What is IKT's ROIC (return on invested capital)?
Inhibikase Therapeutics, Inc. (IKT)'s trailing twelve month Return on Invested Capital (ROIC) is -105.14% as of 2026-06-30.
What is IKT's EV/EBITDA?
Inhibikase Therapeutics, Inc. (IKT)'s trailing twelve month EV/EBITDA is -4.94x as of 2026-06-30.